Medite Cancer Diagnostics (Medite Cancer Diagnostics) LT-Debt-to-Total-Asset : 0.29 (As of Sep. 2018)

View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Medite Cancer Diagnostics's long-term debt to total assests ratio for the quarter that ended in Sep. 2018 was 0.29.

Medite Cancer Diagnostics's long-term debt to total assets ratio increased from Sep. 2017 (0.24) to Sep. 2018 (0.29). It may suggest that Medite Cancer Diagnostics is progressively becoming more dependent on debt to grow their business.

Medite Cancer Diagnostics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Medite Cancer Diagnostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics LT-Debt-to-Total-Asset Chart

Medite Cancer Diagnostics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.19

0.07

0.05

0.01

0.31

Medite Cancer Diagnostics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.24	0.31	0.32	0.33	0.29

Medite Cancer Diagnostics LT-Debt-to-Total-Asset Calculation

Medite Cancer Diagnostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

LT Debt to Total Assets (A: Dec. 2017 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2017 )	/	Total Assets (A: Dec. 2017 )
	=	4.914	/	15.956
	=	0.31

Medite Cancer Diagnostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2018 is calculated as

LT Debt to Total Assets (Q: Sep. 2018 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2018 )	/	Total Assets (Q: Sep. 2018 )
	=	5.1	/	17.651
	=	0.29

Medite Cancer Diagnostics (OTCPK:MDIT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Medite Cancer Diagnostics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4203 SouthWest 34th Street, Orlando, FL, USA, 32811

Website

http://www.medite-group.com

Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

Executives

Lewis William Austin Iv	director, 10 percent owner	201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles	director	2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson	director	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines